Cargando…
Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
Development of immunotherapy agents has changed the cancer treatment paradigm with better outcomes and lesser side effects. Yet, there are adverse events associated with them. Owing to the increased stimulation of the immune system, the normal homeostatic mechanisms protecting the body from its own...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072166/ https://www.ncbi.nlm.nih.gov/pubmed/35528796 http://dx.doi.org/10.1016/j.apjon.2021.12.007 |
_version_ | 1784700998722256896 |
---|---|
author | Shankar, Abhishek Wallbridge, Isaac G. Yau, Callum Saini, Deepak Roy, Shubham Bharati, Sachidanand Jee Mishra, Seema Singh, Pritanjali Seth, Tulika |
author_facet | Shankar, Abhishek Wallbridge, Isaac G. Yau, Callum Saini, Deepak Roy, Shubham Bharati, Sachidanand Jee Mishra, Seema Singh, Pritanjali Seth, Tulika |
author_sort | Shankar, Abhishek |
collection | PubMed |
description | Development of immunotherapy agents has changed the cancer treatment paradigm with better outcomes and lesser side effects. Yet, there are adverse events associated with them. Owing to the increased stimulation of the immune system, the normal homeostatic mechanisms protecting the body from its own immune response can become disrupted, leading to a variety of side effects termed immune-related adverse effects (irAEs). irAEs can have significant associated morbidity and in many cases lead to discontinuation of therapies with unpredictable impact on the course of patients' disease. Few key articles laying out guidelines for the management of irAEs provide general treatment algorithms for the majority of the common irAEs. Nurses should have knowledge of the mechanism and adverse events associated with such therapies. Oncology nurses have a crucial role in identification of irAEs. irAEs may involve multiple systems, and thus, it is necessary to identify and manage these adverse events according to the case these at soon as possible. |
format | Online Article Text |
id | pubmed-9072166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90721662022-05-07 Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment Shankar, Abhishek Wallbridge, Isaac G. Yau, Callum Saini, Deepak Roy, Shubham Bharati, Sachidanand Jee Mishra, Seema Singh, Pritanjali Seth, Tulika Asia Pac J Oncol Nurs Perspective Development of immunotherapy agents has changed the cancer treatment paradigm with better outcomes and lesser side effects. Yet, there are adverse events associated with them. Owing to the increased stimulation of the immune system, the normal homeostatic mechanisms protecting the body from its own immune response can become disrupted, leading to a variety of side effects termed immune-related adverse effects (irAEs). irAEs can have significant associated morbidity and in many cases lead to discontinuation of therapies with unpredictable impact on the course of patients' disease. Few key articles laying out guidelines for the management of irAEs provide general treatment algorithms for the majority of the common irAEs. Nurses should have knowledge of the mechanism and adverse events associated with such therapies. Oncology nurses have a crucial role in identification of irAEs. irAEs may involve multiple systems, and thus, it is necessary to identify and manage these adverse events according to the case these at soon as possible. Elsevier 2021-12-25 /pmc/articles/PMC9072166/ /pubmed/35528796 http://dx.doi.org/10.1016/j.apjon.2021.12.007 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Perspective Shankar, Abhishek Wallbridge, Isaac G. Yau, Callum Saini, Deepak Roy, Shubham Bharati, Sachidanand Jee Mishra, Seema Singh, Pritanjali Seth, Tulika Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment |
title | Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment |
title_full | Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment |
title_fullStr | Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment |
title_full_unstemmed | Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment |
title_short | Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment |
title_sort | development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072166/ https://www.ncbi.nlm.nih.gov/pubmed/35528796 http://dx.doi.org/10.1016/j.apjon.2021.12.007 |
work_keys_str_mv | AT shankarabhishek developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT wallbridgeisaacg developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT yaucallum developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT sainideepak developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT royshubham developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT bharatisachidanandjee developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT mishraseema developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT singhpritanjali developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment AT sethtulika developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment |